Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ve) advanced breast cancer .We have retrospectively evaluated the outcome of patients with HER-2+ve locally advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Waddell, T, Kotsori, A, Constantinidou, A, Yousaf, N, Ashley, S, Parton, M, Allen, M, Starling, N, Papadopoulos, P, O'Brien, M, Smith, I, Johnston, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111155/
https://www.ncbi.nlm.nih.gov/pubmed/21522147
http://dx.doi.org/10.1038/bjc.2011.138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111155/
https://www.ncbi.nlm.nih.gov/pubmed/21522147
http://dx.doi.org/10.1038/bjc.2011.138

Ejemplares similares